Clinical Trial Update: An Open-label, Multicenter Study to Assess the Pharmacokinetics (PK), Safety, and Tolerability of Subcutaneous IgPro20 in Immunoglobulin (IG) Treatment-naïve Participants With Primary Immunodeficiency (PID) [Phase 4]

View source ↗

Summary

An open-label, multicenter Phase 4 study to evaluate the pharmacokinetics, safety, and tolerability of subcutaneous IgPro20 in treatment-naïve participants with…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immunodeficiency

Drugs mentioned

• IgPro20 (intravenous immunoglobulin 20% solution)

Snippet

Sponsor: CSL Behring | Conditions: Primary Immunodeficiency | Phase 4 | Status: ACTIVE_NOT_RECRUITING